Krsnaa Diagnostics Limited has informed the Exchange about Investor Presentation
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics reported strong Q4 FY26 results with PAT jumping 102% YoY to ₹417 million, boosted by a ₹221.75 million fair valuation gain on Apulki Healthcare investment. Full-year FY26 revenue grew 8% to ₹7,728 million with EBITDA margin expanding 69 basis points to 28% and PAT margin improving 231 basis points to 13%. The company operates 190 CT/MRI centres, 147 pathology labs, and 4,700+ collection centres across 18 states. Management disclosed plans to scale CT/MRI centres to 200+ and expand Rajasthan pathology network to 7 reference labs, 41 mother labs, and 5,000+ collection centres. Retail segment showed strong growth with revenue per patient more than doubling from ₹711 to ₹1,503.
The doubling of PAT and margin expansion demonstrates operational efficiency improvements and volume growth, which should be positive for shareholder returns. The disclosed order book pipeline and expansion plans provide visibility on future revenue growth.